Abstract Number: 1L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Results of the 2-Year Primary Analysis from a 5-Year Randomised, Placebo-Controlled, Phase II Study
Background/Purpose: Sprifermin, a novel recombinant human fibroblast growth factor-18 is currently investigated as a potential disease-modifying osteoarthritis (OA) drug. Two-year primary data from a 5-year…Abstract Number: 17L • 2017 ACR/ARHP Annual Meeting
Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study
Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has shown significant and rapid efficacy in psoriatic arthritis (PsA). We present primary results…Abstract Number: 2L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis
Background/Purpose: Interleukin-23 (IL-23), a key regulator of multiple effector cytokines (including IL-17, IL-22, and TNF), has been implicated in psoriatic lesions, synovitis, enthesitis, and bone…Abstract Number: 18L • 2017 ACR/ARHP Annual Meeting
Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
Background/Purpose: RITAZAREM (ClinicalTrials.gov: NCT01697267) is an international, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy after induction of remission with rituximab and glucocorticoids…Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…Abstract Number: 4L • 2017 ACR/ARHP Annual Meeting
Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition causing fibro-inflammatory lesions that can lead to irreversible organ damage and death. No approved therapies exist. A…Abstract Number: 5L • 2017 ACR/ARHP Annual Meeting
Rapamycin Vs. Placebo for the Treatment of Inclusion Body Myositis: Improvement of the 6 Min Walking Distance, a Functional Scale, the FVC and Muscle Quantitative MRI
Background/Purpose: Inclusion body Myositis (IBM) is the most frequent myositis in patients over 50 years old. Conventional immunosuppressive drugs are today ineffective or even aggravate…Abstract Number: 6L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study
Background/Purpose: The IL-12/23 pathway has been implicated in the pathogenesis of SLE. The anti-IL12/23 monoclonal antibody ustekinumab (UST) is efficacious in the treatment of psoriasis,…Abstract Number: 7L • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
Background/Purpose: Effective treatment options are limited for refractory skin disease in dermatomyositis (DM). Anabasum is a non-immunosuppressive, synthetic, oral preferential CB2 agonist that triggers resolution…Abstract Number: 8L • 2017 ACR/ARHP Annual Meeting
Prevalence of Blindness in a Cohort of Rheumatologic Patients Treated with Hydroxychloroquine
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of chronic rheumatic diseases. Its long-standing use has been associated with retinopathy in a daily and…Abstract Number: 9L • 2017 ACR/ARHP Annual Meeting
Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
Background/Purpose: Serum induced IFN gene expression (IFN-score) is considered a golden standard to assess IFN activity in SLE. So far, IFN-scores have not been compared…Abstract Number: 10L • 2017 ACR/ARHP Annual Meeting
Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor
Background/Purpose: Upadacitinib (ABT-494, UPA), an oral, selective JAK-1 inhibitor was effective in 2 ph2 trials in rheumatoid arthritis (RA) pts with inadequate response (IR)/intolerance to…Abstract Number: 11L • 2017 ACR/ARHP Annual Meeting
Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study
Background/Purpose: The safety of treatment with biological DMARDs (bDMARDs) has been carefully studied for the past 15 years, however, it is still largely unknown whether…Abstract Number: 12L • 2017 ACR/ARHP Annual Meeting
Evaluation of Intravenous Injection of Tc 99m Tilmanocept in Static Planar Gamma Emission Imaging and Fused SPECT/CT Imaging for Rheumatoid Arthritis
Background/Purpose: Activated macrophages play a critical role in RA by perpetuating inflammation via TNFα release and participating in the destruction of bone and cartilage. Notably,…Abstract Number: 13L • 2017 ACR/ARHP Annual Meeting
Significant, Sustained Improvement in Knee Function after Intra-Articular TPX-100: A Double-Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2 Trial
Background/Purpose: The current Phase 2 study was designed to evaluate safety, tolerability and preliminary efficacy of TPX-100 by IA administration in subjects with mild to…
ACR Meeting Abstracts